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Abstract
Background: Cell death mode has been studied in cancer, autoimmune, and neurodegenerative
diseases. In this study, apoptosis and necrosis are investigated for the first time in patients with
chronic calculous cholecystitis.
Methods and materials: Thirty five (35) patients (27 women and 8 men, aged 55.65 ± 13.48
years) with symptomatic chronic calculous cholecystitis underwent laparoscopic cholecystectomy.
The early specific apoptotic tendency (caspase-cleaved cytokeratin 18) was studied in these
patients with M30 Apoptosense ELISA and the total cytokerarin 18 (both derived from apoptosis
and necrosis) with M65 ELISA. The ratio M30/M65 (caspase-cleaved to total cytokeratin 18) was
also computed. According to the histopathological examination, the patients were divided in two
groups: group A included patients with chronic inactive cholecystitis (n = 10), and group B those
with chronic active cholecystitis (n = 25).
Results: The concentrations of caspase-cleaved cytokerarin 18 (CK18), and especially those of
total CK18, were higher in bile samples than in serum samples. In group B, there were significant
differences between serum and bile samples regarding both caspase-cleaved CK18 and total CK18.
Cells staining positive for caspase-cleaved CK18 were present in the epithelial cells of the mucosa
of the gallbladder.
Conclusion: CK18 is expressed in the gallbladder epithelial cells. The concentrations of both
caspase-cleaved CK18 and total CK18 were higher in bile samples than in serum samples. The
levels of total CK18, as well as caspase-cleaved CK18, do not seem to differ between active and
inactive chronic cholecystitis.
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Background
Cytokeratins (epithelial keratins) are an important com-
ponent of the intermediate filament system. They are
mainly insoluble molecules playing an important role in
cellular mechanics (cell shape, motility, division and cell-
cell contact). There are two types of cytokeratins: a) Type
I (9–20) keratins that are relatively acidic and bearing a
small molecular weight (40–56.5 kDa), and b) Type II (1–
8) that are relatively basic-neutral of larger molecular
weight (53–67 kDa) [1]. Proliferating cells have a substan-
tial pool of two soluble cytokeratins, namely CK8 and
CK18, and their concentration is high during the G2-M
phase of the cell cycle [2]. During apoptosis, CK18 are
cleaved by caspases at position Asp396 producing rela-
tively stable fragments [3-8]. These fragments can be
detected in cells, sera and other tissue fluids being a
biomarker of apoptosis, while soluble intact CK18 may be
released during both necrosis and apoptosis. In this way,
the ratio of fragment/intact CK18 (i.e., caspase-cleaved to
total CK18) may be a helpful tool in quantifying apopto-
sis and necrosis during various pathological conditions.
In an attempt to study the process of cell death in the gall-
bladder epithelium of patients with chronic cholecystitis
and cholelithiasis, we examined the concentration of
CK18 and its neo-epitope M30 released after CK18 cas-
pase-mediated cleavage in the sera and bile of these
patients. Furthermore, immunohistochemistry was per-
formed to confirm the presence of apoptotic CK18 frag-
ments in the gallbladder epithelium.
Methods
Patients
This prospective study was performed at the University
Hospital of Alexandroupolis, 2nd Department of Surgery,
Medical School, Democritus University of Thrace. Thirty
five (35) patients (27 women and 8 men, aged 55.65 ±
13.48 years) suffering from chronic calculous cholecystitis
were included. Four gallbladder epithelium control sam-
ples were also added in the study. The samples were from
patients not suffering from chololithiasis and cholecysti-
tis. All patients underwent laparoscopic cholecystectomy.
The patients signed a written consent and did not receive
any monetary compensation for participating in the
study. The study was approved by the Democritus Univer-
sity Ethics Committee.
Serum and bile samples were collected before any manip-
ulation of patients. The serum samples were collected pre-
operatively. The bile samples were collected after trocar
entry. All samples were aliquoted and kept frozen at -
75°C for further analysis. Tissue of the gallbladder of all
patients was received and was sent to the pathologist.
Detection of apoptosis was performed in formalin fixed
and paraffin embedded tissue sections from the gallblad-
der samples with immunohistochemistry. The gallbladder
specimens were classified according to the histopatholog-
ical report in two groups: group A included patients with
chronic inactive cholecystitis (n = 10), and group B those
with chronic active cholecystitis (n = 25).
Measurements of CK18 in serum and bile samples
In serum and bile samples, the caspase-cleaved CK18 and
the total CK18 were detected by commercially available
ELISA kits. Caspase-cleaved CK18 was measured with
M30-Apoptosence assay (Peviva, Bromma, Sweden). This
assay uses a mouse monoclonal antibody detecting a neo-
epitope, only formed upon caspase-cleavage of CK18 at
position Asp396. Therefore, values obtained by M30-
Apoptosence assay represent the apoptotic cell death.
Total CK18 was measured with M65 ELISA kit (Peviva,
Bromma, Sweden), which uses two mouse monoclonal
antibodies specific for conventional epitopes on CK18.
Thus, values obtained with M65 represent the total cell
death (both apoptosis and necrosis). The ratio of the val-
ues obtained by M30 and M65 represent the ratio of apop-
tosis to total cell death.
Since both ELISA kits were not validated for bile samples,
validation tests were run in order to determine if the kit
reagents are suitable for this type of samples. Namely, for
M65 ELISA kit, a "recovery" experiment was designed as
follows: A well mixed bile sample was diluted 1:4 and
split into two aliquots. One aliquot was run as "neat sam-
ple". The other aliquot was spiked with the high standard
(2000 U/l): 40 μ of the high standard were mixed with
160 μ of the bile sample – this was the "spiked sample". A
"spiked control" was also prepared by mixing 15 μ of the
high standard with 60 μ of diluent. These samples were
measured and the recovery rate was determined with the
formula: [(spiked sample – neat sample)/spiked control]
– 100. This experiment was repeated three times with
three different bile samples. The recovery rates were 136–
155%. Furthermore, serial dilutions of the spiked samples
were prepared: 1:2, 1:4 and 1:8. The parallelism of the
diluted spiked samples to the standard curve was satisfac-
tory.
For M30 ELISA kit, the parallelism to the standard curve
was checked with multiple dilutions of three bile samples:
1:2, 1:4, 1:8, 1:16. The samples were diluted with 0 stand-
ards. There were satisfactory results for the dilutions 1:4,
1:8 and 1:16.
For the ELISA measurements, an automatic washing sys-
tem for microplates (Multiwash Plus, TRI Continent, NY,
USA) and a microplate reader at 450 nm (Anthos, Labtec
Instr., Salzburg, Austria) were used. All samples were run
in duplicate. Bile samples were diluted 1:4 or 1:8 with the
appropriate diluent.BMC Gastroenterology 2008, 8:14 http://www.biomedcentral.com/1471-230X/8/14
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Detection of caspase-cleaved CK18 in the epithelium of 
the gallbladder
The presence of caspase-cleaved CK18 was investigated in
gallbladder tissue sections with M30 CytoDeath Mono-
clonal Antibody (Peviva, Bromma, Sweden) for all 35
patients. Sections were deparaffinised, placed in antigen
unmasking buffer pH 6.0 (Trilogy, DAKO, Denmark) and
microwaving was followed (3 × 4 min). Peroxidase was
quenched with methanol and H2O2 3% for 15 minutes.
The primary antibody (concentration 2 μg/ml/1:50) was
applied overnight at room temperature. The Envision kit
(DAKO, Denmark) was used for the subsequent steps. The
color was developed by 15 min incubation with DAB
solution and sections were weakly counterstained with
hematoxylin. Normal rabbit immunoglobulin-G was sub-
stituted for the primary antibody as the negative control,
at the same concentration as the primary antibody. The
immunoreactivity of the M30 CytoDeath antibody was
assessed in the cytoplasm of the epithelial cells of the gall-
bladder mucosa.
Statistical analysis
Statistical analysis included descriptive statistics and com-
parisons between studied groups. As studied parameters
did not follow the normal distribution (tested with Kol-
mogorov-Smirnov test for normality), non-parametric
statistical tests were used. Comparisons between groups
were performed with Mann-Whitney U test. Comparisons
between serum and bile samples within groups were per-
formed with Wilcoxon matched pairs test. The two-tailed
significant level was set at p < 0.05. The software used for
statistical analysis was STATISTICA 6.0 (StatSoft Inc.,
Tulsa, OK, USA). Values are given as mean ± standard
deviation.
Results
CK18 in both forms, total and caspase-cleaved, was
detected in all samples of both groups. The levels of the
two forms of CK18 in groups A and B in both the serum
and the bile samples are presented in Table 1. There were
no significant differences between the two groups.
In general, the concentrations of both caspase-cleaved
CK18 and total CK18 were higher in bile samples than in
serum samples. In group B, the differences between serum
and bile samples were significant regarding both caspase-
cleaved CK18 (Wilcoxon matched pairs test: Z = 3.296, p
= 0.001) and total CK18 (Wilcoxon matched pairs test: Z
= 2.981, p = 0.003).
The relatively high levels of both caspase-cleaved CK18
and total CK18 detected in the bile compared to the
serum, led us to use immunohistochemistry examination,
with the monoclonal antibody M30 CytoDeath, to detect
apoptosis (caspase-cleaved CK18) in the epithelial cells of
the mucosa of the gallbladder. Figure 1 shows the staining
of the cytoplasm of the epithelials cells of the mucosa of
the gallbladder. Cells staining positive for caspase-cleaved
CK18 were present in the epithelial cells in the group of
chronic active cholecystitis. M30 was not expressed in
acalculous gallbladder epithelia from four patients not
suffering from cholecystitis (Figure 2).
Discussion
The presence of increased caspase-cleaved CK18 serum
levels in cancer patients has been recently presented, and
seems to be a useful diagnostic marker for these patients
[7,9-12]. Increased caspase-cleaved CK18 serum levels
were found in primary and recurrent breast cancer
patients, and in cancer patients with a large number of
organs involved [10]. Increased serum levels of caspase-
cleaved CK18 were also associated with trauma patients,
patients with viral and autoimmune hepatitis of the liver,
and liver transplant patients [13-17]. Therefore, the possi-
bility that apoptosis may generate circulating products
detectable in the serum and/or in other body fluids has an
important diagnostic potential. In addition, there is an
increasing interest on the diagnostic potential of both
forms of CK18 (i.e., caspase-cleaved and total) in various,
other than cancer, diseases, since the ratio of the two
forms of CK18 seems to determine reliably the proportion
of apoptosis within the total cell death [18-20]. Different
studies showed that serum levels of M30-antigen and
M65-antigen may be of clinical usefulness to identify
patients with liver disease [21-23].
Table 1: Caspase-cleaved CK18 (U/l), total CK18 (U/l) and their ratio in serum and bile samples. 
Group A Group B Two-tailed p
Serum Caspase-cleaved CK18 (U/l) 292.550 ± 192.121 207.356 ± 139.373 0.231
Total CK18 (U/l) 579.100 ± 372.171 431.286 ± 183.045 0.257
Ratio: Caspase-cleaved CK18/total CK18 0.581 ± 0.173 0.583 ± 0.503 0.130
Bile Caspase-cleaved CK18 (U/l) 963.280 ± 308.69 1490.571 ± 1045.862 0.186
Total CK18 (U/l) 3292.360 ± 3041.213 5305.875 ± 2177.843 0.160
Ratio: Caspase-cleaved CK18/total CK18 1.319 ± 2.288 0.598 ± 1.083 0.770
Values are presented as mean ± standard deviation. The comparisons were performed by Mann-Whitney U-test.BMC Gastroenterology 2008, 8:14 http://www.biomedcentral.com/1471-230X/8/14
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In this study, for the first time, the presence of both forms
of CK18 in the bile of calculous cholecystitis patients was
investigated. Caspase-cleaved CK18 was also studied in
the gallbladder epithelium of these patients. Comparison
was made between the levels of both caspase-cleaved
CK18 and total CK18 in the bile and the serum, in order
to see if apoptosis in the gallbladder of patients with calc-
ulous cholecystitis is a local phenomenon. Although, sig-
nificant differences between the two groups of the study
were not detected, it was shown that both forms of CK18
can be detected in bile of the patients with cholecystitis.
Higher concentrations of both caspase-cleaved CK18 and
total CK18 were measured in bile samples compared to
serum samples, suggesting that cell death is prominent in
the gallbladder, and that apoptosis and necrosis are local
phenomena. The results of the immunohistochemical
examination also confirmed apoptosis, with presence of
caspase-cleaved CK18 in epithelial cells of the gallbladder.
In a previous study, Yanagisawa et al. examined the prolif-
erative and apoptotic processes in patients with chronic
cholecystitis [24]. Reactive proliferation of epithelial cells
was noted using the Ki67 proliferation index, accompany-
ing a clear apoptotic tendency of the gallbladder mucosa,
confirmed by the intense p21WAF1 protein expression, a
down-stream protein of the activated wild-type p53 gene,
which is a key step of the apoptotic process [25]. This find-
ing is in full accordance with our observation that CK18
apoptotic fragments are present in the gallbladder
mucosa, bile and sera of patients with active cholecystitis.
On the other hand, no apoptosis was observed in acalcu-
lous non-cholecystitis gallbladder epithelia.
Conclusion
CK18 is expressed in the gallbladder epithelial cells and in
the bile. The concentrations of both caspase-cleaved CK18
and total CK18 were higher in bile samples than in serum
samples. The levels of total CK18, as well as caspase-
cleaved CK18, do not seem to differ between active and
inactive chronic cholecystitis.
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